© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Dopamine’s story began back in the early 20th century. Researchers in the 1910s and 1920s looked to plants and animal tissues, isolating catecholamines in the quest to map how the nervous system works. Dopamine got its name in the 1950s, during the golden era of neurotransmitter discovery. Scientists soon uncovered its dual identity—acting both as a crucial neurotransmitter in the brain and as a chemical messenger elsewhere in the body. I remember reading about Arvid Carlsson’s work: by demonstrating that dopamine wasn’t just a precursor for norepinephrine but a vital neurotransmitter in its own right, Carlsson unlocked a whole field of research that led to everything from new psychiatric medications to better understanding of Parkinson’s disease. By the 1960s, pharmaceutical manufacturing of dopamine hydrochloride had started, aiming to meet the needs of clinics treating cardiac and shock patients. The interest never slowed, and every decade seems to add new layers of detail to what dopamine can do and how it gets used.
3-Hydroxytyramine Hydrochloride, more familiar under the name Dopamine Hydrochloride, is a molecule found both as an essential biological neurotransmitter and a therapeutic agent. Phamaceutical companies supply this compound in sterile solutions for intravenous administration, often as a clear, colorless to slightly pale yellow liquid. For medical applications, handlers keep dopamine hydrochloride solutions at controlled temperatures and away from light to prevent oxidation and loss of potency. Large-scale suppliers focus on tight purity standards and batch consistency because even minor impurities or breakdown products could mean the difference between benefit and risk in vulnerable patients.
Dopamine hydrochloride appears as a white or almost white, crystalline powder, freely soluble in water but less so in alcohol. Its melting point ranges from 248 to 250°C with decomposition. It dissolves rapidly in water, giving clear solutions, which tend to darken if exposed to air because oxidation transforms the catechol group. This chemical sensitivity means manufacturers package dopamine products under inert gas or with antioxidants mixed in, to slow oxidative browning. Its molecular formula reads C8H12ClNO2, with a molecular weight of 189.64 g/mol. The hydrochloride form stabilizes dopamine, making it easier to handle, manipulate, and deliver in clinical settings.
Every dopamine hydrochloride product follows tight technical specs to meet both pharmacopoeial and national health standards. Labels will state the chemical’s name, its concentration (often 40 mg/mL in injection solutions), the batch number, manufacturing date, expiry, storage requirements, and handling cautions. Drug manufacturers include precise instructions, emphasizing sterility and single-use dosing to cut infection risk. You’ll find reference to compliance with US Pharmacopeia (USP) or European Pharmacopoeia (Ph. Eur.) standards on every ampoule. Labelling also reminds users to avoid use after color changes, as signs of oxidation flag reduced potency and increased risk. Shelf lives rarely stretch longer than two years.
Labs and industry chemists make dopamine hydrochloride through chemical synthesis, starting from 3,4-dihydroxybenzaldehyde. Synthesis routes typically reduce or condense the starting material to form 3,4-dihydroxyphenylacetaldehyde, followed by amination and subsequent hydrochloride salt formation. Purification steps involve repeated crystallization and precise pH adjustment, to ensure removal of byproducts and containment of oxidation. Unlike years ago, nearly all preparation happens under inert atmosphere with specialized glassware, to protect the reactive catechol structure. Final products go through sterile filtration for injectable solutions, followed by filling into sealed ampules.
Dopamine readily undergoes reactions typical of catecholamines: oxidation, methylation, and conjugation. Exposed to air or alkaline conditions, dopamine oxidizes quickly into neuromelanin pigments. Protective measures involve antioxidants or pH stabilization. In the body, enzymes like monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) break dopamine down via oxidative deamination or O-methylation. Chemists leverage this reactivity to study enzyme activity with labeled dopamine derivatives or to build prodrugs where dopamine gets masked by protecting groups, improving stability or allowing slow release. Some research uses dopamine’s catechol group to anchor molecules to gold surfaces or nanoparticles, expanding its use into materials science.
Beyond “Dopamine Hydrochloride,” this compound travels under several tags: 3,4-dihydroxyphenethylamine hydrochloride, Intropin (a registered brand), and sometimes simplified as DA·HCl in research catalogs. In clinical literature, “dopamine HCl” shows up commonly. These various names echo across pharmacopoeias, drug registries, and supplier catalogs, each variant tied to either the pure substance or a trademarked injectable preparation. One learns quickly to look for alternate names in searches, to avoid missing clinical trials or chemical safety sheets tucked under a different heading.
Handling dopamine hydrochloride in labs or hospitals asks for care. Direct skin contact can irritate, and accidental aerosols or powder inhalation pose respiratory hazards. Workers wear gloves, eye shields, and masks. Injectable dopamine always goes under medical supervision, because extravasation of the drug can cause severe tissue damage. Hospitals train staff to dilute and administer dopamine using infusion pumps, keeping heart rate and blood pressure under watch, since the drug acts quickly and powerfully as a vasopressor. Medical guidelines stress careful dosing and strong documentation for each use. Transport and storage rules focus on temperature and light controls, with regular stock checks to discard discolored or outdated vials.
In modern clinics, dopamine hydrochloride serves as a mainstay to support blood pressure in critical care settings, treat cardiogenic and septic shock, and help in advanced heart failure. Doctors use it to maintain blood flow to vital organs during crisis. Outside hospitals, dopamine appears in laboratory research on brain chemistry, Parkinson’s disease models, and drug screening platforms. My own time in neuroscience research taught me the value of dopamine as a tool to probe synaptic signaling, receptor modulation, and neurodegeneration. Animal studies employ dopamine to model the biochemical events that drive reward, learning, and movement. Its reach even touches biomanufacturing, where engineered bacteria may be coaxed to produce dopamine for more sustainable supply chains.
Pharmaceutical and academic labs still find new ways to probe dopamine’s effects. Programs aim to design longer-lasting analogs or targeted dopamine prodrugs that activate only in select tissues. Drug makers test advanced delivery systems—infusion pumps, transdermal patches, or even implantable devices—to stretch dopamine activity and reduce risks. Research groups harness dopamine-modified nanoparticles for targeted drug delivery in cancer or brain diseases. Synthetic biology efforts try to construct microbial strains for on-demand dopamine production, offering cheaper, greener ways of manufacture. Every year, the flood of published studies grows—each deepening the chemical’s clinical and technological role.
Toxicologists pay careful attention to dopamine hydrochloride. Too much dopamine can drive dangerous spikes in blood pressure, coronary spasm, or arrhythmias. Toxic doses in rodents and other models reveal potential for myocardial necrosis and acute renal blood flow loss. Chronic exposure, even at moderate levels, links to oxidative stress and cellular injury, driven by the ease with which dopamine oxidizes to toxic quinones. Clinical safety studies focus heavily on dose-response curves and patient selection, since people with coronary artery disease or arrhythmia risk can tip from benefit to harm with a small error. Antidotes and countermeasures exist, but prevention through dose diligence remains the safest path.
Developments on the horizon include next-generation dopamine analogs designed for delayed release, improved crossing of the blood-brain barrier, or reduced side effects. Brain-targeted dopamine prodrugs stand to transform Parkinson’s treatment, bringing more natural dopamine balance without wild motor fluctuations. The rise of stem-cell therapies and engineered tissue brings talk of using dopamine in cell culture to create more physiologically authentic neurons for research and transplantation. On the green-tech side, biosynthesized dopamine could enable more affordable, scalable sourcing for both medicine and specialty materials built around catechol-based adhesives and coatings. Regulatory agencies and researchers will have to keep close tabs on any new delivery systems or manufacturing changes, but the prospects for creative dopamine chemistry look far from exhausted.
Hospitals never stop looking for ways to support patients’ hearts and minds, and 3-Hydroxytyramine Hydrochloride—better known as Dopamine Hydrochloride—serves as one of the more reliable tools for doctors. You’ll see it in emergency rooms and intensive care units. This compound plays a steady role in keeping blood pressure up when people go into shock, especially after trauma, severe infection, or a heart problem. A doctor once told me about the discomfort of watching a patient’s blood pressure drop dangerously low and finding relief only after administering dopamine. It isn’t theory—it’s real relief, provided within minutes thanks to a science-backed medication.
The reason dopamine steps in so well boils down to how the body runs under stress. Blood vessels and the heart need to stay alert and active; dopamine triggers those vessels to tighten up and helps the heart pump with a bit more force. Decades of research, from early cardiac studies to modern intensive care guidelines, highlight its benefits in restoring blood pressure and urine output. The American Heart Association lists dopamine as one of a few trusted agents for managing certain types of shock that leave the kidneys under stress and threaten vital organs.
On some floors, doctors use dopamine to get the kidneys back into action when people stop producing urine, a common issue in intensive care. It isn’t a cure-all, but for acute heart or kidney problems, experts sometimes favor dopamine to jump-start blood flow and improve kidney function. Clinical experience tells us, though, that its window of usefulness remains narrow. Overuse or high doses bring risks, like irregular heart rhythms, which drive home the point that good training and careful watches matter as much as the drug itself.
Researchers also use dopamine hydrochloride as a tool in studies exploring how neurotransmission affects everything from Parkinson’s symptoms to hormonal responses. In some experimental setups on animals, dopamine helps us understand the underpinnings of reward cycles and motivation. Each round of careful laboratory work offers a chance to refine future treatments for neurological diseases and mood disorders.
I’ve spoken with ICU nurses who appreciate what dopamine can do, but they also remind me of the limits. This medication doesn’t replace the need to figure out the root of a patient’s shock or kidney failure—it just buys time. In a world of quick fixes, dopamine’s story teaches the value of precision and context in medicine.
Staying updated on dosing guidelines, tracking patients’ responses, and weighing dopamine against other options all keep healthcare practices rooted in up-to-date science. Organizations like the National Institutes of Health and the FDA regularly update protocols and warn against routine use when other, safer alternatives work just as well. Simple communication between teams and clear guidelines make the most difference.
Seeing dopamine used well in the ER or ICU always feels like teamwork between modern medicine and fast-thinking staff. Practical training, evidence from large clinical trials, and openness to new science make this medicine more effective in the hands of people who listen to both their patients and the latest trusted studies.
3-Hydroxytyramine Hydrochloride, better known as dopamine hydrochloride, pops up often in conversations about neurotransmitters and neuropharmacology. It’s used in both research and clinical settings. Even though its significance continues to grow in academic and medical circles, confusion lingers about what dosage is appropriate and safe for people.
Dopamine hydrochloride isn't something to mess with outside medical supervision. In hospitals, it often plays a role as a life-saving agent for shock, low blood pressure, or certain heart conditions. In my years following hospital pharmacology, nurses and physicians adjust this drug with precision and watchful eyes—not a decision taken lightly.
Standard guidelines suggest dopamine hydrochloride gets started through intravenous infusion, usually starting at 2-5 micrograms per kilogram of body weight per minute. Doses might tick upward, sometimes reaching 20 micrograms/kg/min, depending on the patient’s blood pressure response and heart’s workload. Straying above that risks side effects like irregular heartbeats or excess blood pressure swings, which doctors want to avoid. On the flip side, going too low often means missing the therapeutic effect entirely.
For researchers working in the lab, the story changes. Here, “dose” usually depends on what species and experiment are involved. Mice and rats might get 10 to 40 mg/kg, delivered either via injection or another route. That’s why reading every paper’s method section closely matters—a reminder that nothing beats context.
Too little dopamine hydrochloride accomplishes nothing. Too much sets off symptoms: chest pain, pounding heartbeats, headaches. After years following toxicology cases, I have seen the trouble that comes after even well-meaning oversteps. These drugs demand careful hands.
True, the body makes its own dopamine naturally, but once introduced as a drug, the landscape shifts. Dosing by science—not gut feeling or internet guesswork—can be the difference between healing and harm.
No shortcut skips the need for individual attention. Medical histories, concurrent medications, kidney health, and patient age all shape what a safe dose looks like. Something as simple as a child’s different metabolism or an older person’s slowed clearance can tip the scale.
Health agencies like the FDA only green-light dopamine hydrochloride for certain conditions. Their guidelines follow heaps of trials and safety reports. Local protocols often echo these, but still, no one treats the recommended dosing as a “one-size-fits-all” rule.
Access to information keeps improving, but no web search replaces the doctor-patient conversation. In hospitals, regular blood pressure checks, ECGs, and lab work back every change in dose. For anyone outside the clinic, sticking to approved uses and shunning self-experimentation keeps dangers at bay.
As science learns more about neurotransmitters and their power, careful dosing and trust in experience become more important. The best results come from that blend—grounded science, hands-on expertise, and real-world vigilance.
3-Hydroxytyramine Hydrochloride, known as dopamine hydrochloride, features in many medical conversations. The body produces dopamine naturally because it’s a big player in how the brain transmits signals. Scientists and doctors have tried to tap into its benefits for treatment—sometimes to kick-start a flagging heart, sometimes to keep blood flowing during surgery, or occasionally in neurological research.
Medicating with 3-Hydroxytyramine Hydrochloride doesn’t mirror the tiny and precise doses our bodies make each second. Pharmaceutical doses, delivered through injection, often bring side effects. These can range from small annoyances to severe complications, and experience has shown how easy it is to tip the balance.
Many folks feel their heart racing or notice uneven beats—palpitations. There’s a real jolt to the system. Doses aimed at supporting blood pressure can push the numbers too high. That simple bump leads to headaches. Sometimes hands tremble, or sweat breaks out unexpectedly, as the body tries to counteract the sudden flood of dopamine.
One unwelcome surprise is nausea. Hospitals often see patients turning pale or even vomiting if the medicine isn’t properly adjusted. Watching someone go through that makes the issue clear: dopamine swings don’t just shake the brain; they churn the stomach too.
Careless use can spiral. A quick story: During my clinical rounds, blood pressure spiked for one patient receiving dopamine hydrochloride, landing them in a hypertensive crisis. In that moment, it didn’t just feel risky—it was.
Gangrene has been reported in rare cases where the drug leaks under the skin or when high doses cut off blood to the extremities. In patients with heart problems, dopamine can cause arrhythmias—irregular heartbeats—leading to fainting, chest pain, and even cardiac arrest.
There’s no sugarcoating it: The drug’s impact stretches far beyond a quick fix. That lesson stuck with me—and with my colleagues, watching the difference made by vigilance and teamwork.
People with a history of heart rhythm problems need special consideration. So do children, older adults, and those with circulation issues. Research and medical guidelines both warn against using it in individuals with certain types of tumors or those taking MAO inhibitors for depression because of the serious interactions.
Precise monitoring changes the game. Healthcare teams use heart monitors and check blood pressure constantly during administration. Doses scale up or down minute by minute based on how the body reacts. The lesson is clear: no one-size-fits-all dosing exists. Hospitals set protocols for administering the drug in big emergencies. That’s necessary, considering the risks.
Researchers still look for ways to safely get the benefits of dopamine-like drugs without the cascading side effects. For now, education counts—a careful team, informed patients, and the willingness to revisit every plan with new facts on hand.
Seeing patients react so differently to the same dose drives home a simple truth: powerful medications demand respect. Balance, not shortcuts, keeps people safe. Frequent communication between doctors and families is essential. In healthcare, that’s the piece that saves more than any medicine ever could.
3-Hydroxytyramine Hydrochloride, better known in scientific circles as Dopamine HCl, comes with strict guidelines for storage. Anyone who has worked around biologically active chemicals knows that mishandling can spell danger for both research and personal safety. This compound doesn’t forgive careless storage. Warmth, humidity, light, and air turn it into a risky powder, both for your work and your health.
Some might think a shelf in the supply closet will do the trick. With Dopamine HCl, that shortcut leads straight to instability. The compound prefers a dry, cool, dark environment. A refrigerator, set around 2 to 8 degrees Celsius, gives this powder its best shot at a long shelf life. From past lab experience, forgetting to double-bag the vial can wreck a batch overnight thanks to moisture creeping in. Sealing containers tight changes everything. Direct contact with the air causes degradation. A desiccator provides the backup needed, especially if the chemical sits out on your bench between experiments.
I remember a colleague who once left a just-opened bottle exposed on the lab bench during lunch. Two hours later, the white powder turned slightly brown and wouldn’t pass quality control the next day. Valuable work lost, just like that. The lesson sticks: lid on, bagged, and back to the fridge as soon as possible. Lightproof bottles make sense too. Light exposure triggers oxidation, and oxidized dopamine stops working for most biological studies. Researchers sometimes use amber vials if transparent containers are unavailable, but any light-blocking option beats clear glass.
Without clear labeling, confusion creeps in fast. I make a point of dating every vial, noting who opened it. Tracking origin keeps spoiled batches away from important work. Regulatory guidelines in major labs push the same standard. I’ve seen poorly labeled containers trashed during inspections, and nobody wants to redo time-consuming synthesis or wait for new shipments just because of a scribbled label.
Leaving chemicals unsecured just invites trouble. Dopamine HCl, while not the most toxic compound, still deserves respect. Anyone in a shared space knows stories of cross-contamination, accidental misuse, or, worse, injuries. Personal protective equipment, like gloves and lab coats, blocks exposure and keeps workspaces clean. A careless spill on a warm day can send powder into the air. Keeping storage away from eating areas matters too. I learned early on that labs maintaining strict storage separation avoid expensive accidents and regulatory headaches.
Outdated powder shouldn’t just go in the trash. Regulations require disposal as hazardous waste. Flushing it or tossing it in regular bins risks environmental harm. Most institutions have waste coordinators who’ll take over from there. Following these guidelines spares everyone fines and dangerous situations.
All this boils down to responsibility. Safe storage builds trust with colleagues, protects you, and preserves the compound’s usefulness. A few simple steps can prevent ruined experiments, wasted budgets, or safety scares. It pays off to treat Dopamine HCl with care—your research, reputation, and health depend on it.
3-Hydroxytyramine Hydrochloride, known as dopamine hydrochloride, has a strong reputation in medical circles because doctors use it for certain types of shock or blood pressure support. Dopamine acts as a neurotransmitter in the brain but takes on a whole different life as a drug in hospital settings, especially when people’s bodies just can't keep up their blood flow or organ function on their own.
Dopamine doesn’t work in a vacuum. It influences many systems, so anyone using it needs to stay aware of other medications or conditions that could multiply the risks. Based on my experience in health communication, I have seen confusion and near-misses in the intensive care unit, particularly when patients come in with long medication lists. Anything that ramps up or blunts the effects of dopamine changes the patient’s outcome quickly.
MAO inhibitors—typically used for depression—stand out as major players here. Mixing monoamine oxidase inhibitors with dopamine leads to dangerously high blood pressure. Even if someone stopped an MAOI recently, the risk lingers for a couple of weeks. For patients who have been treated with these antidepressants, doctors either wait or use a different approach altogether.
Tricyclic antidepressants also push blood pressure higher. Dopamine plus these drugs creates a recipe for severe hypertension, headaches, or worse. Similar issues happen with some general anesthetics like halothane. Anesthesiologists generally keep a close watch and often steer clear from certain combinations during surgery.
I’ve also seen that patients with heart rhythm drugs—like beta-blockers—can experience unpredictable swings between high and low blood pressure, or even irregular heartbeats. These situations need quick adjustment and regular monitoring. Medical teams work closely together because slowing the heart while trying to improve circulation gets complicated.
Dopamine infusions create extra challenges for people who already struggle with blood flow problems. For instance, if someone has advanced peripheral vascular disease, the narrowing in their veins and arteries can get so much worse that body parts don’t receive enough oxygen. Even those with diabetes might find themselves at higher risk and require constant checks on their limb health.
Folks with phaeochromocytoma—a rare tumor on the adrenal gland—face serious danger if they get dopamine. They’re already swimming in excess adrenaline-type chemicals, so adding dopamine can set off a hypertensive crisis. Here, doctors look for other medications to avoid disaster.
The American Heart Association and trusted medical journals like The New England Journal of Medicine highlight these interactions and complications. Nurses and pharmacists double-check doses, hospital computers flag dangerous combos, and continuing education keeps everyone up to speed. These safety nets reflect countless stories—the rushed calls to clarify medication histories, the quick hands adjusting IV pumps, and the relief of catching interactions just in time.
Electronic health records make a difference by showing interaction alerts. Patients and families who know the medication list or keep it written down help a lot too. No one should feel awkward for double-checking what’s going in the intravenous line. Every voice matters in spotting possible three-way collisions—between dopamine, other drugs, and health problems already in the mix.
Dopamine hydrochloride gives hope in tough times, but it also calls for teamwork and vigilance. Recognizing interactions and respecting the stories behind every prescription keep people safer—one careful step at a time.
| Names | |
| Preferred IUPAC name | 4-(2-Aminoethyl)benzene-1,2-diol hydrochloride |
| Other names |
Dopamine hydrochloride Dopamine HCl 3-Hydroxytyramine hydrochloride Hydroxytyramine hydrochloride 4-(2-Aminoethyl)benzene-1,2-diol hydrochloride |
| Pronunciation | /ˈθriː haɪˈdrɒk.siˌtɪə.rəˌmiːn haɪˌdrɒk.ləˈraɪd/ |
| Identifiers | |
| CAS Number | 62-31-7 |
| 3D model (JSmol) | `3D model (JSmol)` string for **3-Hydroxytyramine Hydrochloride (Dopamine Hydrochloride)**: ``` CNCCc1ccc(O)cc1.Cl ``` This is the **SMILES** string, which can be used in JSmol or other molecular viewers to render the 3D structure. |
| Beilstein Reference | 3567552 |
| ChEBI | CHEBI:63638 |
| ChEMBL | CHEMBL112 |
| ChemSpider | 12014 |
| DrugBank | DB00988 |
| ECHA InfoCard | 03dbb0af-e3d7-4f14-bafb-8fc6aab46a69 |
| EC Number | 1.10.99.1 |
| Gmelin Reference | 8736 |
| KEGG | C03758 |
| MeSH | Dopamine |
| PubChem CID | 5794 |
| RTECS number | KH8575000 |
| UNII | VTD58M6ZUI |
| UN number | UN1851 |
| Properties | |
| Chemical formula | C8H12ClNO2 |
| Molar mass | 189.64 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -2.0 |
| Acidity (pKa) | 8.9 (for the conjugate acid form) |
| Basicity (pKb) | 8.9 |
| Magnetic susceptibility (χ) | Diamagnetic |
| Refractive index (nD) | 1.659 |
| Dipole moment | 13.2 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 175.1 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -236.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -217.3 kJ/mol |
| Pharmacology | |
| ATC code | C01CA04 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes serious eye irritation, may cause respiratory irritation |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | Precautionary statements: P261, P280, P305+P351+P338, P304+P340, P337+P313 |
| NFPA 704 (fire diamond) | 1-2-0-∞ |
| LD50 (median dose) | LD50 (median dose): Mouse intravenous 55 mg/kg |
| NIOSH | NS6134000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 10 mg/m³ |
| IDLH (Immediate danger) | ND |
| Related compounds | |
| Related compounds |
Norepinephrine Epinephrine Tyrosine L-DOPA Methyldopa Dopamine 3-Methoxytyramine Phenylethylamine Tyramine |
